Peginterferon Pharmacokinetics in African American and Caucasian American Patients With Hepatitis C Virus Genotype 1 Infection

Clinical Gastroenterology and Hepatology

Volumn 6, Issue 5, 2008, Pages 575-583

  Howell, Charles D ^a   Dowling, Thomas C ^b   Paul, Marika ^c   Wahed, Abdus S ^c   Terrault, Norah A ^d   Taylor, Milton ^e   Jeffers, Lennox ^f   Hoofnagle, Jay H ^g  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e INDIANA UNIVERSITY   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,5 OLIGOADENYLATE SYNTHETASE; PEGINTERFERON ALPHA2A; RIBAVIRIN; SYNTHETASE; VIRUS RNA;

ADULT; AFRICAN AMERICAN; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME BLOOD LEVEL; ENZYME INDUCTION; EUROPEAN AMERICAN; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AGED; AREA UNDER CURVE; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; VIRAL LOAD;

EID: 42749091580     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2008.02.035     Document Type: Article

References (21)

1. Alter M.J., Kruszon-Moran D., Nainan O.V., et al. The prevalence of hepatitis C infection in the United States, 1988 through 1999. N Engl J Med 341 (1999) 556-562
2. Muir A.J., Bornstein J.D., and Killenberg P.G. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 350 (2004) 2265-2271
3. Jeffers L., Cassidy W., Howell C.D., et al. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic hepatitis C virus genotype 1. Hepatology 39 (2004) 1702-1708
4. Conjeevaram H.S., Fried M.W., Jeffers L.J., et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with chronic hepatitis C genotype 1. Gastroenterology 31 (2006) 470-477
5. Stark G.R., Kerr I.M., Williams B.R.G., et al. How cells respond to interferons. Annu Rev Biochem 67 (1998) 227-264
6. Ji X., Cheung R., Cooper S., et al. Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. Hepatology 37 (2003) 610-621
7. Glue P., Rouzier-Panis R., Raffanel C., et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology 32 (2000) 647-653
8. Sulkowski M., Wright T., Rossi S., et al. Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. Clin Pharmacol Ther 77 (2005) 214-224
9. Di Bisceglie A.M., Fan X., Chambers T., et al. Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: the null responder. J Med Virol 78 (2006) 446-451
10. Sowinski K.M., Burlew B.S., and Johnson J.A. Racial differences in sensitivity to the negative chronotropic effects of propranolol in healthy men. Clin Pharmacol Ther 57 (1995) 678-683
11. Sowinski K.M., Lima J.J., Burlew B.S., et al. Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. Br J Clin Pharmacol 42 (1996) 339-346
12. Hershman D., Weinberg M., Rosner Z., et al. Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer. J Natl Cancer Inst 95 (2003) 1545-1548
13. Ribaudo H.J., Haas D.W., Tierney C., et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis 42 (2006) 401-407
14. Jen J.F., Glue P., Ezzet F., et al. Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C. Clin Pharmacol Ther 69 (2001) 407-421
15. Silva M., Poo J., Wagner F., et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol 45 (2006) 204-213
16. Chen L., Borozan I., Feld J., et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128 (2005) 437-444
17. Taylor M.W., Tsukahara T., Brodsky L., et al. Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol 81 (2007) 3391-3401
18. He X.S., Ji X., Hale M.B., et al. Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. Hepatology 44 (2006) 352-359
19. Lam N.P., Pitrak D., Speralakis R., et al. Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C. Dig Dis Sci 42 (1997) 178-185
20. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
21. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C. N Engl J Med 347 (2002) 975-982